-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shandong New Times' enoxaparin sodium injection category 4 generic listing application has entered the administrative approval process, which is expected to usher in good news
.
Enoxaparin sodium injection is the best-selling injection among antithrombotic drugs, and only 3 companies have reviewed it
.
Figure 1: Shandong New Era's product registration progress Source: NMPA official website Enoxaparin sodium injection is a low molecular weight heparin, mainly used for the treatment of symptoms such as anticoagulation and antithrombosis, and for the prevention and treatment of thrombosis or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.
)
.
Figure 2: Sales of Enoxaparin Sodium Injection (unit: RMB 10,000) Source: MINET China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have terminal sales of more than 2.
3 billion yuan, with double-digit growth in the first half of 2021, occupying the TOP1 of antithrombotic injection products.
location
.
Under the impact of domestic brands, the market share of the original research company Sanofi has continued to decline.
In 2015, the original research drugs accounted for 83.
75%, and only 54.
11% in the first half of 2021.
Among the domestic brands, Nanjing Jianyou Biochemical Pharmaceutical, Shenzhen Tiandao Medicine, and Hangzhou Jiuyuan Gene's market share.
The market share will be above 10% in the first half of 2021
.
Figure 3: Over-evaluation of enoxaparin sodium injection Source: Consistency Evaluation Database of Minet Successful approval will be regarded as over-evaluation, and will become the fourth over-evaluation company
.
Up to now, the number of products that have been reviewed by Shandong New Times has reached 18.
In the field of antithrombotic drugs, rivaroxaban tablets have been approved according to the new classification as being reviewed
.
Source: NMPA official website, Minet database Note: The statistics are as of April 20.
If there are any omissions, please correct me!
.
Enoxaparin sodium injection is the best-selling injection among antithrombotic drugs, and only 3 companies have reviewed it
.
Figure 1: Shandong New Era's product registration progress Source: NMPA official website Enoxaparin sodium injection is a low molecular weight heparin, mainly used for the treatment of symptoms such as anticoagulation and antithrombosis, and for the prevention and treatment of thrombosis or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.
)
.
Figure 2: Sales of Enoxaparin Sodium Injection (unit: RMB 10,000) Source: MINET China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have terminal sales of more than 2.
3 billion yuan, with double-digit growth in the first half of 2021, occupying the TOP1 of antithrombotic injection products.
location
.
Under the impact of domestic brands, the market share of the original research company Sanofi has continued to decline.
In 2015, the original research drugs accounted for 83.
75%, and only 54.
11% in the first half of 2021.
Among the domestic brands, Nanjing Jianyou Biochemical Pharmaceutical, Shenzhen Tiandao Medicine, and Hangzhou Jiuyuan Gene's market share.
The market share will be above 10% in the first half of 2021
.
Figure 3: Over-evaluation of enoxaparin sodium injection Source: Consistency Evaluation Database of Minet Successful approval will be regarded as over-evaluation, and will become the fourth over-evaluation company
.
Up to now, the number of products that have been reviewed by Shandong New Times has reached 18.
In the field of antithrombotic drugs, rivaroxaban tablets have been approved according to the new classification as being reviewed
.
Source: NMPA official website, Minet database Note: The statistics are as of April 20.
If there are any omissions, please correct me!
